Cannabis Edibles for Parkinson's Tremor: What the Trials Actually Show

The evidence on cannabis for Parkinson's tremor is mixed, and the mix runs in one direction. Patients report relief in surveys and in open-label studies where they know what they took. Placebo-controlled trials mostly find no motor benefit at all. And the side effects land on exactly the weak points of the disease: THC brings dizziness, low blood pressure on standing, slowed thinking and falls to people who are already prone to every one of them.

So the position here is narrow. A CBD-leaning, low-THC edible is a reasonable thing to discuss with a neurologist as an anxiety-and-sleep tool that sometimes quiets the tremor that anxiety makes worse. It is never a tremor drug, and it never replaces levodopa or anything else on the prescription list. The one CBD signal in the trial record comes from a single dose taken before a stressful task, and the products on shelves carry a small fraction of that dose. This is the fifth page in our Neurological cluster.

Does cannabis help Parkinson's tremor?

Not in controlled trials. Smoked cannabis improved tremor scores 30 minutes after use in an open-label study of 22 patients, and nearly half of users in a Prague survey described some benefit. Every blinded trial of oral cannabis or CBD, from 2004 to 2024, found motor scores no better than placebo.

The survey came first. Venderová and colleagues mailed an anonymous questionnaire to every patient at the Prague Movement Disorder Centre and published the result in 2004: 25% of 339 respondents had taken cannabis, and 45.9% of those described some form of benefit. Ten years later Lotan's group in Israel examined 22 patients at baseline and again 30 minutes after smoking cannabis. Motor UPDRS scores fell from 33.1 to 23.2, with significant improvement in tremor, rigidity and slowness of movement, plus better sleep and pain scores. No placebo, no blinding, and the authors called for controlled studies themselves.

The controlled studies came back flat. Carroll and colleagues ran a randomized double-blind crossover in 2004, 19 patients with levodopa-induced dyskinesia taking oral cannabis extract or placebo for four weeks each. Seventeen finished, and the extract was well tolerated with no pro- or antiparkinsonian action on any measure, objective or subjective. Chagas's 2014 exploratory trial gave 21 patients placebo, 75 mg or 300 mg of CBD a day for six weeks. UPDRS scores did not move, though the 300 mg group scored better on the PDQ-39 quality-of-life questionnaire. The largest and most recent, Liu and Leehey's 2024 Colorado trial, randomized 61 people to a high-CBD, low-THC extract or placebo for two weeks, with a mean final daily dose of 191.8 mg CBD and 6.4 mg THC. Motor MDS-UPDRS fell 4.57 points on extract and 2.77 on placebo, and the gap between them was not significant.

Why do patient surveys and controlled trials disagree?

Because the studies that find benefit let patients know what they took, and the ones that blind them find a large placebo response. Lotan's patients smoked cannabis and were scored half an hour later, while the trials used swallowed extract or CBD and compared it against a dummy. Expectation, route and timing all differ.

Parkinson's is unusually sensitive to expectation. In the Colorado trial the placebo arm improved significantly on its own, and the authors wrote that several assessments had a strong placebo response. A survey cannot separate that effect from the drug, and an open-label study only measures it. Then there is route. Smoked cannabis reaches the brain in minutes and Lotan scored patients at 30 minutes. An edible takes 30 minutes to 2 hours to begin working by the standard onset on our edible duration guide and peaks 2 to 3 hours after eating, so the 30-minute snapshot transfers poorly to a gummy. Tremor itself rises with stress (the de Faria trial below provoked it on purpose), so a relaxed afternoon after a joint shows up on a tremor score whatever caused the relaxation. A good afternoon is a real afternoon. It is a weak test of a drug.

Does CBD help tremor that gets worse with anxiety?

In one small trial, yes. De Faria and colleagues gave 24 people with Parkinson's a single 300 mg dose of CBD or placebo, two weeks apart, before a simulated public speaking test. CBD lowered self-rated anxiety and reduced tremor amplitude measured by an accelerometer. It is the only controlled tremor signal for any cannabinoid in Parkinson's.

The design matters for reading it. The public speaking test is built to provoke anxiety, and the tremor being measured was the tremor that anxiety produced, so the result says CBD dampened a stress response rather than the underlying motor disease. It fits with Chagas's quality-of-life finding at the same 300 mg dose, and with a 2009 open-label pilot by Zuardi in six patients with Parkinson's psychosis, where flexible CBD doses starting at 150 mg a day eased psychotic symptoms without worsening motor function. All three come from the same University of São Paulo group at Ribeirão Preto, with small numbers each time.

Now the arithmetic. A Wyld Peach gummy carries 10 mg of CBD. Reaching the 300 mg in the de Faria trial would take thirty gummies, delivering 150 mg of THC along the way, a dose nobody should take and nobody studied. Matching the Colorado trial's 192 mg of CBD would mean nineteen pieces and 96 mg of THC. Retail CBD-leaning edibles sit a long way under trial CBD doses, so what they offer this population is a lower THC dose with some CBD alongside, and their labels are best read that way. Our anxiety page covers the CBD dosing evidence for anxiety in people without Parkinson's.

What are the THC risks for people with Parkinson's?

Low blood pressure on standing, falls, slowed thinking and sedation that stacks with other drugs. A 2011 meta-analysis put orthostatic hypotension in about 30% of people with Parkinson's. The dronabinol label warns of orthostatic hypotension and fainting, says elderly patients are more sensitive, and calls for fall precautions in elderly patients with dementia.

Velseboer's meta-analysis pooled 25 studies to a point prevalence of 30.1%, with wide variation between them. Dronabinol is synthetic THC in a capsule, the closest thing to an edible with an FDA label, and the label says its effects on blood pressure are inconsistent while subjects have experienced orthostatic hypotension or syncope on abrupt standing. It tells prescribers to consider a lower starting dose in elderly patients and to put patients with dementia on fall precautions, because somnolence and dizziness add to a fall risk the disease already carries. Parkinson's adds slowed gait and postural instability to that picture.

Cognition and sleep are the other column. In the Colorado trial, cognition, sleep and activities of daily living showed a treatment effect favoring placebo, and adverse events were more common on the extract, at only 6.4 mg of THC a day. Sedation stacks with sleep medications, benzodiazepines and opioids, and the dronabinol label tells prescribers to avoid combining it with drugs that have similar effects. A night-time dose followed by a bathroom trip at 3 a.m. is the abrupt standing the label's warning describes. Talk to your neurologist before trying any THC product, bring the full medication list to a pharmacist, and never change a prescribed dose on the strength of how a gummy felt.

Is a gummy or a tincture easier to dose with a hand tremor?

A pre-dosed gummy or mint, because nothing has to be measured. A tincture dropper asks a shaking hand to fill to a fraction of a millimeter or count drops under the tongue, and a missed drop is an unknown dose. A piece is a fixed number on a label, though very small mints can be hard to pick up.

That cuts both ways for the three products below. The Wyld gummy weighs 4 g per piece by its nutrition panel, big enough to pick up off a table. The Petra mint weighs 0.75 g, under a fifth of the gummy and easy to chase across a countertop, and it comes forty to a tin. A weekly pill organizer loaded by a steadier hand fixes both problems and doubles as a dose log. Halving a gummy with a knife is the step most likely to go wrong with a tremor, so whole pieces at the right size beat a big piece cut down. The low tier on our dosing guide is 2.5 to 5 mg THC, and the Canadian Centre on Substance Use and Addiction puts the first-timer ceiling at 2.5 mg. The products were checked against their brand sites and priced on dispensary menus on October 21, 2026:

The Petra mint is the lowest dose on a single piece, 2.5 mg of each cannabinoid, at about 59 cents a mint on the San Rafael menu, and its size is the trade. The Papa & Barkley gummy is a 5 mg THC piece with equal CBD, and only the California-licensed version belongs here; the brand-site version is hemp-derived. Weedmaps now lists the licensed one as Pear Apple Releaf. The Wyld Peach has the most CBD per piece and the easiest grip, and it is also the one to argue with. Its 5 mg of THC is a whole step above the 2.5 mg starting point with no clean way to halve it, and its 10 mg of CBD is a thirtieth of the dose that moved tremor in the de Faria trial. Wyld files it under Chill, a word that describes the marketing better than the pharmacology.

How is this different from MS spasticity?

The trial record is far stronger for MS. Large placebo-controlled trials of oral cannabis extract and the nabiximols spray found that people with MS rated their own stiffness and spasms better than placebo did, and a spray is licensed in markets outside the US. Parkinson's has no positive placebo-controlled motor trial and no licensed cannabinoid product.

The comparison is useful because the two diseases split along the same seam. In MS the clinician's muscle-tone scale mostly failed while the patient's own rating passed, trial after trial, which is the story on our MS spasticity page. In Parkinson's the patient's impression passes only when the patient knows what they took, and the blinded trials find a placebo group improving almost as much. The MS page can recommend a titrated 1:1 edible as an add-on. This page cannot recommend one for the tremor at all, only for the anxiety and sleep around it.

What Parkinson's cannabis trial is still running?

A phase II trial of oral CBD from the drugmaker Laboratorio Elea Phoenix, registered as NCT06629389, plans 88 participants across three CBD doses and placebo. Its registry record lists it as recruiting, with estimated completion in November 2026. No results have been posted, and this page will report them when they are.

The registry record was last updated in December 2024, so the recruiting status is the sponsor's last word rather than a fresh one. Its stated aim is safety and tolerability across Parkinson's symptoms, and a placebo arm is the feature the open-label literature has always lacked. A positive motor result from it would be the first in this field.